{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:42:22Z","timestamp":1760071342777,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chang Gung Medical Foundation","award":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"],"award-info":[{"award-number":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"]}]},{"DOI":"10.13039\/501100004663","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"],"award-info":[{"award-number":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maintenance Project of the Center of Data Science and Biostatistics at Keelung CGMH","award":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"],"award-info":[{"award-number":["CORPVVP0101","CORPVVP0161","CMRPVVN0231","113-2314-B-182A-062-MY3","CGRPG2F0011","CLRPG2C0021","CLRPG2C0022","CLRPG2C0023","CLRPG2C0024","CLRPG2G0081","CLRPG2G0082","CLRPG2G0083","CLRPG2L0021","CLRPG2L0022","CMRPG2N0041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard care for acute coronary syndrome (ACS). Although ticagrelor showed superiority over clopidogrel in pivotal trials, patients with advanced chronic kidney disease (CKD) or on dialysis were underrepresented and results in Asian populations have been inconsistent. Materials and Methods: We conducted a retrospective cohort study using the Taiwan Society of Cardiology Acute Coronary Syndrome-Diabetes Mellitus (TSOC ACS-DM) registry between 1 October 2013, and 30 September 2016. Eligible patients had type 2 diabetes mellitus and ACS with stage III\u2013V CKD or were on dialysis at index hospitalization and were discharged on aspirin plus either ticagrelor or clopidogrel. The primary endpoint was a composite of cardiovascular (CV) death, CV-related readmission, and repeated revascularization. Cumulative incidence functions were compared using expectation maximization (EM) weighting and propensity score adjustment. Results: After exclusions, 451 patients were analyzed (ticagrelor n = 116; clopidogrel n = 335). Ticagrelor associated with higher myocardial infarction (HR 1.59, 95% CI 1.12\u20132.28, p = 0.010), CV-related readmission (HR 1.72, 95% CI 1.12\u20132.65, p = 0.014), repeated revascularization (HR 2.24, 95% CI 1.36\u20133.68, p = 0.002), and the composite endpoint (HR 1.63, 95% CI 1.06\u20132.48, p = 0.024) at 2 years. Conclusions: Among real-world Taiwanese patients with type 2 diabetes mellitus, ACS, and CKD, ticagrelor use was linked to increased risks of cardiovascular events compared to clopidogrel. However, these relationships might be affected by potential confounding factors. Randomized controlled trials are necessary to establish the best antiplatelet strategy for this high-risk group.<\/jats:p>","DOI":"10.3390\/medicina61101804","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:22:08Z","timestamp":1759911728000},"page":"1804","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndrome and Chronic Kidney Disease: A Real-World Analysis from a National Registry"],"prefix":"10.3390","volume":"61","author":[{"given":"Tzu-Lin","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-4369","authenticated-orcid":false,"given":"Victor Chien-Chia","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-8640","authenticated-orcid":false,"given":"Kou-Gi","family":"Shyu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Chang","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien-Hsing","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung 204, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-713X","authenticated-orcid":false,"given":"Ming-Lung","family":"Tsai","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei 236, Taiwan"},{"name":"College of Management, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.163.10.1145","article-title":"Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the cure study","volume":"163","author":"Jneid","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral p2y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (plato) trial","volume":"157","author":"James","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2010.07.004","article-title":"Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2c19*2 loss of function polymorphism","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: A report of the american college of cardiology foundation\/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 aha\/acc guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the american college of cardiology\/american heart association task force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the european society of cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in plato study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (plato) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"180","author":"Turgeon","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. Clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the platelet inhibition and patient outcomes (plato) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. Clopidogrel in japanese, korean and taiwanese patients with acute coronary syndrome\u2014Randomized, double-blind, phase iii philo study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: A randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tung, Y.C., Chang, C.J., Liu, J.R., Chang, S.H., Chan, Y.H., Kuo, C.T., and See, L.C. (2021). Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: A nationwide cohort study. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-00360-0"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bcp.14935","article-title":"Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in taiwan","volume":"88","author":"Li","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cpt.3209","article-title":"Ticagrelor versus adjusted-dose prasugrel in acute coronary syndrome with percutaneous coronary intervention","volume":"116","author":"Tsai","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","first-page":"211","article-title":"In-hospital implementation of evidence-based medications is associated with improved survival in diabetic patients with acute coronary syndrome\u2014Data from tsoc acs-dm registry","volume":"34","author":"Chen","year":"2018","journal-title":"Acta Cardiol. Sin."},{"key":"ref_18","first-page":"63","article-title":"2012 guidelines of the Taiwan Society of Cardiology (TSOC) for the management of st-segment elevation myocardial infarction","volume":"28","author":"Li","year":"2012","journal-title":"Acta Cardiol. Sin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction: A report of the american college of cardiology foundation\/american heart association task force on practice guidelines","volume":"61","author":"Kushner","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the platelet inhibition and patient outcomes (plato) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised platelet inhibition and patient outcomes (plato) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bcp.13436","article-title":"Pharmacodynamics and pharmacokinetics of ticagrelor vs. Clopidogrel in patients with acute coronary syndromes and chronic kidney disease","volume":"84","author":"Wang","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","first-page":"40","article-title":"Comparative efficacy and safety of oral p2y12 inhibitors for patients with chronic kidney disease and acute coronary syndrome: A network meta-analysis","volume":"63","author":"Farmakis","year":"2022","journal-title":"Hell. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during observation (credo) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast asian paradox\u201d: Challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Jeong","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World heart federation expert consensus statement on antiplatelet therapy in east asian patients with acs or undergoing pci","volume":"11","author":"Levine","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ehjcvp\/pvab042","article-title":"Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease","volume":"8","author":"Franchi","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Rivoli, L., Garofalo, C., Faga, T., Pelagi, E., Perticone, M., Serra, R., Michael, A., Comi, N., and Andreucci, M. (2020). Renal resistive index in chronic kidney disease patients: Possible determinants and risk profile. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230020"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1804\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:14:20Z","timestamp":1760069660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101804"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101804","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}